Glenmark, an Indian pharmaceutical company, has introduced a bio-similar of the diabetes medicine Liraglutide under the brand name Lirafit.

This injectable drug, belonging to the glucagon-like peptide-1 receptor agonists (GLP-1R) class, is known for its weight-loss properties and efficacy in improving insulin sensitivity.

Lirafit is expected to offer a more affordable alternative, potentially reducing prices by 70 percent, making it a cost-effective solution for diabetes management.

While not as potent in weight loss as Semaglutide, another drug gaining popularity, Lirafit is recognized for its positive impact on insulin sensitivity. The standard 1.2 mg dose is priced at Rs 100, significantly lowering the monthly cost to around Rs 3,000 from the current Rs 10,000.

Glenmark's pricing positions Lirafit as not only more economical than the branded version but also more affordable than the competing drug Dulaglutide, which costs approximately Rs 8,000 per month.

Despite its cost-effectiveness, Lirafit faces challenges due to changes in patient preferences since the introduction of Dulaglutide. Many individuals prefer the convenience of a single weekly injection over daily shots, posing a hurdle for the adoption of Lirafit.

Liraglutide, classified as an incretin mimetic, imitates gut hormones to enhance pancreatic beta cell function, slow stomach emptying, and suppress appetite. While not as potent as Semaglutide, which has shown a 15% weight reduction in studies, Liraglutide, along with older GLP-1 receptor agonists like Dulaglutide and Exenatide, is effective for weight loss and HbA1c control.

With the emergence of cost-effective alternatives like Lirafit, the diabetes and weight loss drug market in India is poised for increased competition. However, factors such as the convenience of weekly injectables and the weight loss potential of newer drugs like Tirzepatide may continue to influence patient choices in this evolving landscape.